ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 853,600 shares, a growth of 47.9% from the December 15th total of 577,200 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average trading volume of 162,900 shares, the short-interest ratio is presently 5.2 days.
Analyst Upgrades and Downgrades
ABVX has been the topic of several research reports. JMP Securities restated a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $38.67.
Get Our Latest Stock Report on ABIVAX Société Anonyme
Hedge Funds Weigh In On ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Performance
ABVX opened at $6.29 on Thursday. ABIVAX Société Anonyme has a 1-year low of $5.54 and a 1-year high of $17.02. The company’s fifty day moving average price is $8.22 and its two-hundred day moving average price is $10.33.
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
See Also
- Five stocks we like better than ABIVAX Société Anonyme
- How to Evaluate a Stock Before Buying
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- The 3 Best Fintech Stocks to Buy Now
- How Do Stock Buybacks Affect Shareholders?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.